Computational drug repurposing identifies N-acetylglucosamine as a potential therapeutic compound for CLN3 Batten disease
Elina Casoli, Amali S. Fernando, Juliana C.S. Chaves, Rebecca L. Johnston, Destiny Aranovitch, Sueanne Chear, Anthony L. Cook, Alex William Hewitt, Eske M. Derks, Anthony Robert White, Zachary F. Gerring, Lotta E. Oikari
The paper uses computational drug repurposing to identify N-acetylglucosamine as a potential therapy for CLN3 Batten disease, showing it reduces lipofuscin burden in cell models.
bioRxiv · May 15, 2026 · PreprintNeuroscience